MediciNova, Inc. (Ticker: MNOV) is a biopharmaceutical company that operates with a mission to in-license and develop novel therapeutics for addressing unmet medical needs and effectively increasing patients' satisfaction. The company was founded in September 2000, and it's headquartered in the La Jolla section of San Diego, California. Being publicly traded on the Nasdaq Global Market, MediciNova concentrates its efforts in the research and development of therapies for diseases with high unmet needs in the sectors of neurological disorders and fibrotic diseases, although, its product pipeline involves therapies for several other diseases, including respiratory and cancer disorders.
The pillars of MediciNova's research platform are two promising compounds, MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is a first-in-class, orally bioavailable small molecule phosphodiesterase (PDE) -4 and -10 inhibitor, and a macrophage migration inhibitory factor (MIF) inhibitor, primarily being developed for progressive multiple sclerosis, amyotrophic lateral sclerosis, and other neurological conditions. MN-001 is an orally bioavailable small molecule compound being developed for idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis (NASH), and other fibrotic diseases.
The proactive and dedicated drive towards addressing hard-to-treat conditions has been noticed in MediciNova's research strategy. Every development process follows a focused, prioritized, and sequential process that favors the best therapeutic candidates for additional investment and development.
Another aspect of MediciNova's approach to business is its endeavor to secure strong intellectual property rights and protection for its product candidates. The company's portfolio carries numerous patents for MN-166 and MN-001 across several potential indications, in various jurisdictions globally which can extend into the mid-2030s.
MediciNova has shown its commitment to follow a cost-efficient operation model, while advancing towards novel drug development. This is made possible through strategic alliances and collaborations with leading academic and research institutions. These partnerships align with MediciNova’s goal to in-license or acquire additional compounds or businesses to expand its pipeline.
The ultimate goal of MediciNova, Inc. is to deliver transformative treatments to patients in areas where treatment options are limited. The company aims to make a significant difference in enhancing the quality of life of patients across the globe. The dedicated team at MediciNova is diligently working towards pushing the boundaries of medical innovation to create a healthier world.